Market News & Trends
Inozyme Pharma Announces Authorization to Proceed in US & UK With Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application and that the United Kingdom Medicines and Healthcare…
EyePoint Pharmaceuticals Announces $15.7-Million Equity Investment
EyePoint Pharmaceuticals, Inc. recently announced Ocumension Therapeutics has made a $15.7-million equity investment in EyePoint. Under the terms of the agreement, Ocumension has purchased approximately…
Daré Bioscience Announces Positive Topline Results From Phase 3 Trial
Daré Bioscience, Inc. recently announced positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating DARE-BV1 in 307 women diagnosed with…
Kronos Bio Announces FDA Clearance of IND for Oral CDK9 Inhibitor
Kronos Bio, Inc. recently announced US FDA clearance of the company’s Investigational New Drug (IND) application for KB-0742, a highly selective, orally bioavailable inhibitor of…
Ionis Announces Initiation of the Global Phase 3 BALANCE Study
Ionis Pharmaceuticals, Inc. recently announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familial chylomicronemia syndrome (FCS). FCS is…
Cerner & Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes
Cerner Corporation recently announced an investment in Elligo Health Research, a leading integrated research organization that enables clinical trials with nationwide community-based healthcare practices. Cerner representatives…
Catalent to Invest $10 Million to Expand High Potency Containment Capabilities for Micronization
Catalent recently announced it is investing $10 million in isolator capabilities at its sites in Malvern, PA, and Dartford, UK, to expand its micronization capabilities…
BioAge Raises $90 Million to Treat Aging & Age-Related Diseases
BioAge Labs, Inc. recently announced it has raised $90 million in an oversubscribed Series C financing. The raise was co-led by Andreessen Horowitz and serial…
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results
Galecto, Inc. recently announced the publication of a paper detailing full results from a Phase 2a study of GB0139 in Idiopathic Pulmonary Fibrosis (IPF) in…
Biogen & Sage Therapeutics Announce Global Development & Commercialization Collaboration
Biogen Inc. and Sage Therapeutics, Inc. recently announced they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….